Trial Profile
A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischaemic Stroke in 4.5-6 Hours After Stroke Onset
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2020
Price :
$35
*
At a glance
- Drugs Saruplase (Primary) ; Aspirin
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms PROUD
- Sponsors Tasly Pharmaceuticals, Inc.
- 02 Mar 2020 Status changed from recruiting to completed.
- 09 Jan 2019 Status changed from not yet recruiting to recruiting.
- 12 Jul 2018 New trial record